Source Log · Issue No. 01
BPC-157 Isn't Legal Yet
Every factual claim in Issue No. 01 is listed below in document order, with the source it was checked against. Claims we could not support are listed too, with the reason we cut them.
What this is
The public audit trail behind Issue 01—not a reading list hidden behind the story.
- 45 claims checked
- 20 primary sources logged
- 8 claims cut
Claims verified, by section
Standfirst
| # | Claim | Source |
|---|---|---|
| 1 | RFK Jr. announced on Joe Rogan on Feb 27, 2026 that ~14 previously restricted peptides would come off the "do not compound" list | Frier Levitt legal-firm summary citing the JRE #2461 broadcast — frierlevitt.com |
| 2 | BPC-157 was among them | Same source — frierlevitt.com |
| 3 | FDA followed through six weeks later (April 15, 2026 publication; effective April 22, 2026) | Federal Register notice 2026-07361 — federalregister.gov |
| 4 | The substantive decision happens at the July 23–24 PCAC meeting | FDA's own meeting page — fda.gov |
The 90-second version
| # | Claim | Source |
|---|---|---|
| 5 | Joe Rogan Experience episode #2461 aired Feb 27, 2026 | Shortform podcast index — shortform.com |
| 6 | Kennedy said ~14 of 19 peptides would move from Cat 2 to Cat 1 | Frier Levitt; BioPharma Dive — frierlevitt.com, biopharmadive.com |
| 7 | Kennedy framed the prior classification as illegal | Frier Levitt direct quote summary — frierlevitt.com |
| 8 | April 15, 2026 Federal Register notice removed 12 peptides from Category 2 | Federal Register 2026-07361 — federalregister.gov |
| 9 | Names of peptides removed (BPC-157, TB-500, KPV, MOTs-C, Semax, Epitalon, Emideltide/DSIP) | FDA PCAC meeting page; Orrick summary — fda.gov |
| 10 | Effective date April 22, 2026 (seven calendar days from publication) | Orrick legal analysis — orrick.com |
| 11 | Removal from Cat 2 does not place a substance on 503A bulks list, does not place under interim enforcement-discretion policy, does not authorize compounding | FDA Law Blog; Orrick — thefdalawblog.com |
| 12 | July 23–24, 2026 PCAC meeting at FDA White Oak | FDA meeting page — fda.gov |
What's actually happened so far
| # | Claim | Source |
|---|---|---|
| 13 | March 3, 2026 — FDA issues 30 warning letters to telehealth companies on compounded GLP-1s | FDA press release — fda.gov |
| 14 | Attribution to FDA Commissioner Marty Makary | Same FDA press release |
| 15 | March 31, 2026 — seven warning letters issued to peptide vendors, published April 7 | FDA warning letters (each) — fda.gov |
| 16 | Substances cited were GLP-1 copycats (retatrutide, tirzepatide, mazdutide, cagrilintide), not BPC-157 | Gram Peptides + Prime Sciences letters, direct text |
| 17 | April 15, 2026 Federal Register notice | Federal Register 2026-07361 |
| 18 | April 22, 2026 effective date | Orrick |
| 19 | Docket FDA-2025-N-6895 | FDA meeting page |
The April warning letters
| # | Claim | Source |
|---|---|---|
| 20 | Gram Peptides — MARCS-CMS 721806 | FDA warning letter |
| 21 | Prime Sciences — MARCS-CMS 721805 | FDA warning letter |
| 22 | Lovega LLC dba Pink Pony Peptides — MARCS-CMS 721088 | FDA warning letter |
| 23 | Mile High Compounds LLC — MARCS-CMS 721600 | FDA warning letter |
| 24 | PekCura Labs — MARCS-CMS 721709 | FDA warning letter |
| 25 | FormPour — MARCS-CMS 722215 | RAPS coverage cross-referenced with FDA database — raps.org |
| 26 | Guangzhou Huli Technology Co., Ltd. dba Fantasy Face — MARCS-CMS 722228 | RAPS; safemedicines.org compiled PDF — safemedicines.org |
| 27 | "Research use only" disclaimers do not control intended use when product pages describe physiologic effects | Gram Peptides letter, direct quotation |
| 28 | BPC-157 was not the focus of any of the seven letters | Direct review of Gram Peptides + Prime Sciences + Mile High + Pink Pony letters |
What's on the July 23–24 agenda
| # | Claim | Source |
|---|---|---|
| 29 | Day 1 substances: BPC-157, KPV, TB-500, MOTs-C | FDA meeting page agenda table |
| 30 | Day 2 substances: Emideltide/DSIP, Semax, Epitalon | FDA meeting page agenda table |
| 31 | Indications under review by substance (UC for BPC-157; wound healing for KPV/TB-500; obesity/osteoporosis for MOTs-C; opioid withdrawal/insomnia/narcolepsy for DSIP; cerebral ischemia/migraine/trigeminal neuralgia for Semax; insomnia for Epitalon) | FDA meeting page tables |
| 32 | PCAC recommendations are non-binding; rulemaking required to formalize 503A inclusion | Orrick |
What the careful reader should NOT do
| # | Claim | Source |
|---|---|---|
| 33 | Systematic review screened 544 papers on BPC-157, identified 1 human study | Vasireddi et al. (2025) — pubmed.ncbi.nlm.nih.gov |
| 34 | The single human study was a 12-person knee-pain case series with no control / no blinding | Same systematic review |
| 35 | Phase 1 trial of PCO-02 / Bepecin was cancelled | ClinicalTrials.gov NCT02637284 — clinicaltrials.gov |
| 36 | FDA review at July meeting is scoped specifically to ulcerative colitis | FDA meeting page agenda table |
What we're watching
| # | Claim | Source |
|---|---|---|
| 37 | FDA warning letters database is searchable | FDA database itself — fda.gov |
| 38–40 | Three forward-looking signals (enforcement direction, supply chain transparency, payer behavior) | Framed explicitly as editorial analysis, not asserted as fact — n/a |
Coming Wednesday
| # | Claim | Source |
|---|---|---|
| 41 | Lancet OB/GYN published the HRT + tirzepatide retrospective cohort study on January 22, 2026 | Lancet abstract; Mayo Clinic release |
| 42 | Mayo Clinic–led, retrospective cohort, 120 participants | Same |
| 43 | Population is postmenopausal women (not perimenopausal) | Lancet abstract title and study description |
| 44 | Headline finding: ~35% more weight loss in HRT + tirzepatide group vs. propensity-matched non-users over 12 months | Lancet abstract; Mayo press release |
| 45 | Propensity-matched, not randomized | Mayo Clinic press release; Lancet abstract |
Claims we wanted to make but could NOT verify — and cut
These appeared in an earlier, unverified draft, or were considered for inclusion. Each was checked against a primary source and either found to be wrong, imprecise, or unconfirmable — so it was cut before publication. This is the part of the process we think matters most: showing our work on what didn't make it in.
1. "On February 27, 2026, HHS — under Secretary Robert F. Kennedy Jr. — signaled that twelve peptides, including BPC-157, would return to Category 1 compounding eligibility."
The number twelve was wrong. Kennedy's Joe Rogan statement referenced approximately 14 of 19 peptides. "12" appears only in the April 15 Federal Register notice (12 peptides removed from Category 2), a different action. The published draft uses the actual reported numbers in their correct contexts.
2. "As of today, May 11, 2026, BPC-157 remains on the FDA's Category 2 list — meaning it is still not legally compoundable."
Factually incorrect. BPC-157 was removed from Category 2 effective April 22, 2026. The underlying point (still not legally compoundable) is true, but for a different reason — 503A authorization hasn't happened. Corrected in the published draft.
3. "Each was cited for marketing peptides — including BPC-157 — under the label 'research use only'" (re: the April warning letters).
Direct review of the Gram Peptides, Prime Sciences, Mile High Compounds, and Pink Pony Peptides letters shows the cited substances were GLP-1 copycats, not BPC-157. Corrected.
4. "Day two covers Emideltide (also known as DSIP) and Semax."
Incomplete — the published agenda also includes Epitalon on Day 2. All three now included.
5. "Wednesday's Deep Cut examines the recently published Lancet Obstetrics & Gynecology study on HRT combined with tirzepatide, which found 35% greater weight loss in perimenopausal women compared to tirzepatide alone."
Two errors: the journal is The Lancet Obstetrics, Gynaecology, & Women's Health, and the study population is postmenopausal women, not perimenopausal. Both corrected.
6. Pricing or market-size claims about the BPC-157 compounding market.
No primary source provides a defensible number; trade press estimates vary by an order of magnitude. Omitted entirely rather than guessed.
7. Specific named clinicians or longevity-clinic experts, quoted.
No named expert was already in the source pool, and inventing or paraphrasing a quote would violate the protocol. The systematic-review citation does the same work more rigorously.
8. "Most insurance carriers do not cover compounded peptides."
Softened to "insurance carriers do not cover compounded peptides today" — can't fully confirm a categorical "none" across every self-insured employer plan, but the consensus across multiple trade and legal sources is that no commercial reimbursement architecture exists.
Methodology notes
- Every URL above was retrieved during the May 11–13, 2026 drafting session via web search and direct fetch.
- Where a primary source (FDA, Federal Register, peer-reviewed journal, ClinicalTrials.gov) was available, it was cited in preference to secondary coverage.
- Where only secondary coverage was available (e.g. the Frier Levitt and BioPharma Dive summaries of Kennedy's Joe Rogan statements), the article explicitly notes the source category.
- Three of the seven April warning letters (FormPour, Fantasy Face/Guangzhou Huli, and a second pass on Gram Peptides for double-checking) were verified via the safemedicines.org compiled PDF and the RAPS regulatory press summary. If circumstances change, those three should be re-verified directly against the FDA Warning Letters database.
Think we got something wrong here? Write to corrections@pepcurrent.com with the claim number and your source.